This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Erenumab was initially approved by the United States Food and Drug Administration (FDA) on May 17, 2018.

Mechanism of Action of undefined

Erenumab involves targeting and blocking the calcitonin gene-related peptide (CGRP) receptor. By doing so, it disrupts the signaling pathway responsible for transmitting pain signals and dilating blood vessels, both of which play a role in the development of migraines. This blockade aims to reduce the frequency and severity of migraine attacks, offering a preventive approach to managing migraines in adults.

Uses of undefined

Erenumab is a preventive treatment for individuals who experience frequent migraine attacks. Targeting the calcitonin gene-related peptide (CGRP) receptor aims to reduce migraines' occurrence and severity over time. Administered through monthly subcutaneous injections, it offers a strategy to enhance the quality of life by mitigating the impact of migraines on daily activities and overall well-being. It is important to note that this medication is designed for long-term prevention and is not intended for immediate relief during acute migraine episodes. Its application should be determined by a healthcare provider based on the patient's medical history and specific needs.

undefined Drug administaration and Dosage available

Erenumab is administered as a subcutaneous injection. It is injected under the skin, typically in the abdomen or thigh area, once a month. This route of administration allows the medication to be absorbed into the bloodstream and exert its preventive effects on migraines over time. It's important to follow the proper injection technique and guidelines your healthcare provider provides to ensure the medication is administered correctly and safely.

Warnings, Precautions and Side Effects of undefined


Erenumab can cause serious allergic reactions, including anaphylaxis, may occur. This medication may lead to constipation. It might affect blood pressure. This medication may affect the immune response. Hypersensitivity reactions have been reported, including swelling, tenderness, or skin discomfort at the injection site. Some patients may experience dizziness, vertigo, or altered sensation while taking this medication. Abrupt discontinuation of this medication may lead to an increase in migraine frequency.


If you experience symptoms such as difficulty breathing, facial or throat swelling, or rash, seek immediate medical attention. Consult your healthcare provider if you experience any of hypersensitive reactions. If you experience severe constipation, contact your healthcare provider. Discuss your cardiovascular health with your healthcare provider before starting treatment. Consult your healthcare provider if you have a weakened immune system. Consult your healthcare provider before receiving any vaccines while on this medication. Proper injection technique is important to prevent injection site reactions. Ensure you have been properly trained on how to self-administer erenumab.

Side Effects

Erenumab may lead to a range of side effects, with common ones encompassing injection site reactions, constipation, muscle spasms, fatigue, and nausea. While severe allergic reactions are rare, they require immediate medical attention if experienced. Discussing any side effects with a healthcare provider and adhering to proper administration guidelines is important. Individual responses can vary, and careful monitoring of potential reactions is advised to ensure safe and effective migraine prevention.

Word Of Advice

When using erenumab for migraine prevention, several precautions should be observed. These include monitoring for severe allergic reactions, discussing pregnancy and breastfeeding considerations with your healthcare provider, informing them of liver or kidney conditions, and being aware of potential interactions with other medications. Caution is advised while driving or operating machinery, especially if side effects like dizziness occur. Communicate any history of allergies or immunocompromised conditions and disclose your medical history, including cardiovascular and mental health conditions. Additional precautions involve proper injection techniques, maintaining hydration, and discussing vaccination plans. Pediatric use is not approved, and elderly individuals should consider potential interactions and age-related factors. Regular monitoring of effectiveness and maintaining a healthy lifestyle are important aspects of its responsible use.

Frequently Asked Question


  1. Novartis Europharm Limited, Electronic medicines compendium (EMC), [Revised on 21 Jul 2023] [ Accessed on 8th August 2023],
  2. Aimovig, US Food, and Drug Administration, [Revised on 5/2018] [ Accessed on  08/08/2023]
  3. Anna P.Andreou et al.; The role of erenumab in the treatment of migraine; Therapeutic Advances in Neurological Disorders; Published on 27/05/2020; Accessed on;  8th August 2023
  4. Simona Lattanzi et al.; Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety; Drugs; Published on March 2019; Accessed on  8th August 2023;


The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.